Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 3Sarcoma 1Breast 1

Conditions

Endometrial Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Carcinosarcoma 1Breast Neoplasms 1

Interventions

Carboplatin 11pembrolizumab 10Gemcitabine 8Cisplatin 8Rituximab 7osimertinib 5durvalumab 5Specimen Handling 5Pemetrexed 5Nivolumab 5Dexamethasone 5belzutifan 4atezolizumab 4amivantamab 4Prednisone 4Paclitaxel 4Cyclophosphamide 4Bortezomib 4trastuzumab deruxtecan 3olaparib 3lazertinib 3entrectinib 3enfortumab vedotin 3daratumumab 3alectinib 3acalabrutinib 3X-Rays 3Vinorelbine 3Oxaliplatin 3Midazolam 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has announcements × Paclitaxel × 90 days × Clear all
NCT04269200 2026-06-01

DUO-E

AstraZeneca

Phase 3 Active not recruiting
805 enrolled 18 charts 1 FDA
Gynecologic

Endometrial Neoplasms

NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

AstraZeneca

Phase 3 Active not recruiting
644 enrolled 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
813 enrolled 16 charts 1 FDA
GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03517449 2026-03-19

MK-3475-775

Eisai Inc.

Phase 3 Completed
827 enrolled 34 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡